Drug · Other
Aldesleukin
CI-DRUG-00000690Explore in graph →CHEMBL1201438 Approved
Regulatory
Approvals (5)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-11
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260914-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| US FDA | — | Efficacy supplement 1998-01-09 (see label) | approved | Jan 9, 1998 | openfda |
| US FDA | — | Efficacy supplement 1998-01-09 (see label) | approved | Jan 9, 1998 | openfda |
| US FDA | Renal Cell Carcinoma | The treatment of adults with metastatic renal cell carcinoma. | approved | May 5, 1992 | openfda |
| US FDA | Melanoma | The treatment of adults with metastatic melanoma. | approved | May 5, 1992 | openfda |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 16 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 60 | 41 | 29 | 397 | 5 | CA, US | May 5, 1992 | 1991-04 |
| Malignant Kidney Neoplasm | Approved | Phase 4 | 4 | 2 | 8 | 51 | 1 | US | May 5, 1992 | 1991-04 |
| Malignant Breast Neoplasm | Phase3 | Phase 3 | 9 | 7 | 1 | 31 | 0 | — | — | 1995-02 |
| Cutaneous Melanoma | Phase3 | Phase 3 | 4 | 1 | 1 | 13 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (402)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07288073 | TIL Therapy in cSCC and MCC | recruiting | Phase 2 | 14 | Karam Khaddour, MD, MSOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05493566 | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 15 | Emory University |